Joseph Stringer
Stock Analyst at Needham
(4.86)
# 380
Out of 5,028 analysts
625
Total ratings
46.5%
Success rate
23.6%
Average return
Main Sectors:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Rated: Buy | $110 → $122 | $73.82 | +65.27% | 44 | Oct 5, 2026 | |
| STTK Shattuck Labs | Rated: Buy | $17 → $19 | $6.50 | +192.31% | 7 | Oct 2, 2026 | |
| VIR Vir Biotechnology | Reiterated: Buy | $18 | $11.78 | +52.80% | 48 | Sep 28, 2026 | |
| IONS Ionis Pharmaceuticals | Reiterated: Buy | $86 | $43.50 | +97.70% | 47 | Sep 23, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $357 | $219.89 | +62.35% | 49 | Sep 17, 2026 | |
| BIOA BioAge Labs | Reiterated: Buy | $35 | $6.36 | +450.31% | 8 | Sep 14, 2026 | |
| IFRX InflaRx | Initiated Coverage: Buy | $8 | $1.68 | +376.19% | 1 | Sep 14, 2026 | |
| MRNA Moderna | Reiterated: Hold | n/a | $203.21 | - | 44 | Aug 19, 2026 | |
| ANNX Annexon | Reiterated: Buy | $25 | $4.20 | +495.24% | 39 | Aug 12, 2026 | |
| PLRX Pliant Therapeutics | Reiterated: Hold | n/a | $1.04 | - | 34 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $170 | $144.63 | +17.54% | 31 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $130 | $92.45 | +40.62% | 48 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $25.34 | +57.85% | 46 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $503.50 | - | 33 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 → $22 | $6.70 | +228.36% | 75 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.74 | n/a | 28 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.14 | n/a | 33 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $26 | $20.11 | n/a | 5 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $144.21 | n/a | 3 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $170 | $57.34 | n/a | 2 | Apr 28, 2021 |
Vaxcyte
Oct 5, 2026
Rated: Buy
Price Target: $110 → $122
Current: $73.82
Upside: +65.27%
Shattuck Labs
Oct 2, 2026
Rated: Buy
Price Target: $17 → $19
Current: $6.50
Upside: +192.31%
Vir Biotechnology
Sep 28, 2026
Reiterated: Buy
Price Target: $18
Current: $11.78
Upside: +52.80%
Ionis Pharmaceuticals
Sep 23, 2026
Reiterated: Buy
Price Target: $86
Current: $43.50
Upside: +97.70%
Alnylam Pharmaceuticals
Sep 17, 2026
Reiterated: Buy
Price Target: $357
Current: $219.89
Upside: +62.35%
BioAge Labs
Sep 14, 2026
Reiterated: Buy
Price Target: $35
Current: $6.36
Upside: +450.31%
InflaRx
Sep 14, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $1.68
Upside: +376.19%
Moderna
Aug 19, 2026
Reiterated: Hold
Price Target: n/a
Current: $203.21
Upside: -
Annexon
Aug 12, 2026
Reiterated: Buy
Price Target: $25
Current: $4.20
Upside: +495.24%
Pliant Therapeutics
Aug 12, 2026
Reiterated: Hold
Price Target: n/a
Current: $1.04
Upside: -
Aug 5, 2026
Reiterated: Buy
Price Target: $170
Current: $144.63
Upside: +17.54%
Aug 4, 2026
Reiterated: Buy
Price Target: $130
Current: $92.45
Upside: +40.62%
Aug 4, 2026
Reiterated: Buy
Price Target: $40
Current: $25.34
Upside: +57.85%
Aug 4, 2026
Reiterated: Hold
Price Target: n/a
Current: $503.50
Upside: -
Jul 30, 2026
Reiterated: Buy
Price Target: $28 → $22
Current: $6.70
Upside: +228.36%
Apr 21, 2025
Rated: Hold
Price Target: n/a
Current: $1.74
Upside: n/a
Aug 16, 2024
Rated: Hold
Price Target: n/a
Current: $1.14
Upside: n/a
Aug 5, 2021
Rated: Buy
Price Target: $30 → $26
Current: $20.11
Upside: n/a
Aug 4, 2021
Rated: Hold
Price Target: n/a
Current: $144.21
Upside: n/a
Apr 28, 2021
Rated: Buy
Price Target: $170
Current: $57.34
Upside: n/a